Nawar A. Latif, MD, MPH, MSCE
Assistant Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
Attending, Gynecologic Oncology, Department of Obstetrics & Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA
Attending, Gynecologic Oncology, Department of Obstetrics and Gynecology, Pennsylvania Hospital, Philadelphia, PA
Director, Center for Surgical Excellence in Gynecology and Gynecologic Oncology
Department: Obstetrics and Gynecology
Contact information
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
3400 Civic Center Blvd.
3rd Floor West
Philadelphia, PA 19104
3400 Civic Center Blvd.
3rd Floor West
Philadelphia, PA 19104
Email:
nawar.latif@uphs.upenn.edu
nawar.latif@uphs.upenn.edu
Education:
MD
University of Baghdad, 2002.
MPH (Master of Public Health, Health Policy and Administration, Fulbright scholarship grant)
University of Illinois at Chicago (UIC), 2009.
MSCE (Masters of Science in Clinical Epidemiology)
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, 2016.
Permanent linkMD
University of Baghdad, 2002.
MPH (Master of Public Health, Health Policy and Administration, Fulbright scholarship grant)
University of Illinois at Chicago (UIC), 2009.
MSCE (Masters of Science in Clinical Epidemiology)
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, 2016.
Selected Publications
Nasioudis D, Latif NA, Gysler S, Giuntoli RL 2nd, Kim SH, Ko EM: Premature adoption of adjuvant chemotherapy for locally advanced cervical carcinoma before the OUTBACK trial: cautionary tale on outcomes. Int J Gynecol Cancer 34(12):1874-1880, Dec 2024.Nasioudis D, Labban N, Latif N, Gysler S, Cory L, Kim S, Giuntoli RL 2nd, Ko EM: Role of immunotherapy for lymph node positive vulvar melanoma: utilization and outcomes. Int J Gynecol Cancer 33(9):1347-1353, Sep 2024.
Nasioudis D, Gysler S, Latif NA, Giuntoli RL 2nd, Kim SH, Ko EM: Role of systematic lymphadenectomy at the time of interval debulking surgery for patients with advanced-stage epithelial ovarian carcinoma who achieved complete gross resection. Int J Gynecol Cancer 34(7):969-974, Jul 2024.
Nasioudis D, Gysler S, Latif N, Cory L, Giuntoli RL 2nd, Kim SH, Simpkins F, Martin L, Ko EM : Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions. Gynecol Oncol 180:1-5, Jan 2024.
Nasioudis D, Arevalo O, Gysler S, Ko EM, Cory L, Kim SH, Giuntoli RL 2nd, Latif NA: Impact of delayed interval cytoreductive surgery on the survival of patients with advanced stage high-grade epithelial ovarian carcinoma. Int J Gynecol Cancer 34(1):131-137, Jan 2024.
Nasioudis D, Wang X, Dhillon G, Latif N, Ko EM, Giuntoli RL 2nd, Gershenson D, Fader A, Carey M, Simpkins F: Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery. Int J Gynecol Cancer 33(12):1906-1912, Dec 2023.
Nasioudis D, Gysler S, Latif NA, Ko EM, Cory L, F Simpkins, Kim SH: Utilization and outcomes of sentinel lymph node biopsy (SLNBX) for patients with cervical carcinoma; a multicenter database analysis. Focused ORAL Presentation. International Gynecologic Cancer Society Meeting, Seoul Nov 2023.
Nasioudis D, Latif NA, Ko EM, Cory L, Kim SH, Martin L, Simpkins F, Giuntoli R 2nd: Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma. Gynecol Oncol 177:14-19, Oct 2023.
Nugent ST, Raj LK, Latif NA, Cory L, Tanyi JL, Kovach SJ 3rd, Fischer JP, Fosnot J, Lin IC, Etzkorn JR, Shin TM, Giordano CN, Higgins HW 2nd, Walker JL, Miller CJ: A retrospective case series of Mohs micrographic surgery and interdisciplinary management of female genital skin cancers: Local recurrence rates and patient-reported outcomes. J Am Acad Dermatol 89(2):301-308, Aug 2023.
Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA, Rodriguez D, Smith SA, Dean E, Domchek SM, Drapkin R, Shih IM, Brown EJ, Hwang WT, Armstrong DK, Gaillard S, Giuntoli R, Simpkins F: Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer. Clin Cancer Res 29(15):2800-2807, Aug 2023.